Τα πιστοποιητικά είναι διαθέσιμα!
Registrations
Chairs: G. Papaxoinis (GR), G. Nasioulas (GR), I. Souglakos (GR)
08.30-09.00: ctDNA ready for prime time for CRC? M. Liu (US)
09.00-09.20: State-of-the-Art Management of Rectal Cancer: Treatment Advances and Innovation C. Kontovounisios (GR)
09.20-09.40: Optimal Frontline Therapy and Sequencing in Advanced HCC: VEGF Inhibition with ICI vs Dual Immune Checkpoint Blockade? I. Boukovinas (GR)
09.40-10.00: Perioperative treatment in Stomach Cancer I. Souglakos (GR)
10.00-10.20: New Treatments A. Strimpakos (GR)
10.20-10.30: Discussion
10.30-11:10: Writing a paper, grant or thesis: Consulting from expert S. Karagiannis (UK)
11.10-11.50: Pathways to success: Building a career as
clinician-scientist N. Papadopoulos (US)
12.00-12.20: Early NSCLC El. Vorrias (CY)
12.20-12.40: Early EGFRmut NSCLC A. Tavoulari (GR)
12.40-13.00: Resistance to 1st line treatment in IO/TKIs Ν. Asimakopoulou (GR)
Tumor Board: D. Papadatos-Pastos (UK), F. Dimitrakopoulos (GR), P. Skarlos (GR),
N. Panagiotopoulos (UK), A. Koutsopoulos (GR)
Chairs: Α. Kotsakis (GR), Ch. Charalambous (CY), K.Iliadis (GR)
13.00-13.20: Is a wedge resection equivalent to segmentectomy for a peripheral stage IA1-2 solid NSCLC? K. Vachlas (GR)
13.20-13.40: Is it really more complex to operate on a patient after neoadjuvant chemo-immunotherapy? K. Konstantinidis (GR)
Chairs: D. Papadatos (UK), K. Papagiannopoulos (UK)
14.45-15:05: Update on treatment of mesothelioma carcinoma I. Metaxas (SUI)
15.05-15.25: Biology and novel agents in SCLC F. Dimitrakopoulos (GR)
15.25-15.40: Discussion
Chairs: M. Liontos (GR), E. Lianos (GR)
15.40-16.00: Endometrial Carcinoma non-dMMR: What to Do Now? C. Markellos (GR)
16.00-16.20: Immunotherapy in locally advanced cervical cancer? R. Zakopoulou (GR)
Chairs: M. Liontos (GR), E. Lianos (GR)
17.20-17.40: Case 1 A. Tavoulari (GR)
17.40-18.00: Case 2 A. Lianou (GR)
Tumor board: D. Baltogiannis (GR), I. Athanasiadis (GR), M. Trichas (GR), R. Zakopoulou (GR)
Chairs: Ph. Koinis (GR), P. Vlachostergios (GR)
18.00-18.20: Evolving role of Immunotherapy for MIBC: Exploring the latest clinical evidence P. Grivas (US)
18.20-18.40: Case 1 (Definition and diagnostic algorithm) S. Manolakou (GR)
18.40-19.00: Case 2 (Rising PSA after radical local treatment: Role of systemic treatments) V. Aidarinis (GR)
19.00-19.20: Case 3 (Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical relapse) S. Chrysoglou (GR)
Tumor board: M. Liontos (GR), G. Pissakas (GR), Th. Pipikos (GR), S. Tyritzis (GR)
08.30-08.50: Case 1 Choosing treatment for older patients D. Tryfonopoulos (GR)
08.50-09.10: Case 2 Interdisciplinary management of inflammatory breast cancer S. Douvetzemis (GR)
09.10-09.30: Case 3 Choosing adjuvant therapy based on personal risk for HR+/HER2- breast cancer Α. Konstantis (UK)
09.30-09.50: Case 4 Metastatic ER+ Her2 + N. Tavoulari (GR)
09.50-10.10: Case 5 Post-neoadjuvant decisions in young BRCA carriers with triple-negative breast cancer Th. Foukakis (SWE)
Tumor board: D. Tryfonopoulos (GR), A. Konstantis (UK), S. Douvetzemis (GR),
Ch. Christopoulos (FR), A. Koutras (GR)
Chairs: D. Tryfonopoulos, E. Papadimitraki (UK)
Novel Endocrine Backbones in Breast Cancer: Should We Move Them into Earlier Lines of Therapy? Yes vs No Th. Foukakis (SWE)
Chairs: D. Tryfonopoulos (GR), A. Koutras (GR)
11.00-11.20: The evolving Frontier: Navigating treatment after CDK4/6 inhibition in metastatic breast cancer E. Papadimitraki (UK)
11.20-11.40: Regional nodes: What are the optimal approaches in 2025? S. Chatzopoulos (GR)
11.40-12.00: ER-low: What do we know and don’t know? A. Matikas (SWE)
12.00-12.20: Sequencing or all together in mBC er+/her-2- V. Kaklamanis (US)
12.20-12.30: Discussion
12.50-13.10: Case 1 (Stage III melanoma) D. Ziogas (GR)
13.10-13.30: Case 2 (Locally advanced skin cancer) S. Manolakou (GR)
13.30-13.50: Case 3 (Melanoma) N. Asimakopoulou (GR)
Interdisciplinary tumor board: D. Ziogas (GR), G. Koukourakis (GR), G. Maravelis (GR),
Ch. Christopoulos (FR)
Chairs: D. Bafaloukos (GR), V. Papadopoulos (GR)
13:50-14.10: Adjuvant and neo-adjuvant treatment in melanoma in stage III A. Laskarakis (GR)
Chairs: I. Souglakos (GR), F. Dimitrakopoulos (GR)
14.10-14.40: Neoantigens and T cell therapy G. Coukos (SUI)
14.40-15.10: Tumor Agnostic Therapies - Revolutionizing Cancer Treatment: From Tissue-Specific to Target-Driven P. Christopoulos (DE)
15.10-15.40: MRD and cfDNA: Current Uses and Future Applications from Early Detection to Disease Monitoring V. Anagnostou (US)
Chairs: G. Vasmatzis (US), V. Anagnostou (US)
